Acarix announced that the company has appointed Ms. Helen Ljungdahl Round as head of the company’s newly established US subsidiary Acarix Inc. Helen will assume her position in September 2021 and build the US organization. She will be a member of Acarix AB’s Executive Management Group. Ms. Helen Ljungdahl Round has more than 25 years of experience from executive and global positions in the pharmaceutical industry with Merck & Co Inc. (MSD) and as Senior Vice President Global Marketing & Business Development for GN Hearing. Her most recent position was CEO of Amnicell, a biotech start-up company based in New York City. Helen has spent most of her professional life in the US, where she has worked for American companies, and holding Board and Advisory assignments. She is recognized as a strong commercial leader who builds high performing teams and organizations to delivered profitable and sustainable business results.